{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:13:30Z","timestamp":1791249210210,"version":"4.1.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,5,1]]},"DOI":"10.1093\/hmg\/ddi127","type":"journal-article","created":{"date-parts":[[2005,3,17]],"date-time":"2005-03-17T01:22:51Z","timestamp":1111022571000},"page":"1153-1160","source":"Crossref","is-referenced-by-count":156,"title":["Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans"],"prefix":"10.1093","volume":"14","author":[{"given":"Armelle","family":"Logi\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Dunois-Lard\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Rosty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Levrel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Blanche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marie","family":"Gasc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Jorcano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Sastre-Garau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Paul","family":"Thiery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Radvanyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2005,3,16]]},"reference":[{"key":"key\n\t\t\t\t20171012162401_DDI127C1","unstructured":"Johnson, D.E. and Williams, L.T. (1993) Structural and functional diversity in the FGF receptor multigene family. Adv. Cancer Res., 60, 1\u201341."},{"key":"key\n\t\t\t\t20171012162401_DDI127C2","doi-asserted-by":"crossref","unstructured":"Schlessinger, J. (2000) Cell signaling by receptor tyrosine kinases. Cell, 103, 211\u2013225.","DOI":"10.1016\/S0092-8674(00)00114-8"},{"key":"key\n\t\t\t\t20171012162401_DDI127C3","doi-asserted-by":"crossref","unstructured":"Robertson, S.C., Tynan, J.A. and Donoghue, D.J. (2000) RTK mutations and human syndromes, when good receptors turn bad. Trends Genet., 16, 265\u2013271.","DOI":"10.1016\/S0168-9525(00)02021-7"},{"key":"key\n\t\t\t\t20171012162401_DDI127C4","doi-asserted-by":"crossref","unstructured":"Ornitz, D.M. and Marie, P.J. (2002) FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. Genes Dev., 16, 1446\u20131465.","DOI":"10.1101\/gad.990702"},{"key":"key\n\t\t\t\t20171012162401_DDI127C5","doi-asserted-by":"crossref","unstructured":"Naski, M.C., Wang, Q., Xu, J. and Ornitz, D.M. (1996) Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nat. Genet., 13, 233\u2013237.","DOI":"10.1038\/ng0696-233"},{"key":"key\n\t\t\t\t20171012162401_DDI127C6","doi-asserted-by":"crossref","unstructured":"Chesi, M., Nardini, E., Brents, L.A., Schrock, E., Ried, T., Kuehl, W.M. and Bergsagel, P.L. (1997) Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat. Genet., 16, 260\u2013264.","DOI":"10.1038\/ng0797-260"},{"key":"key\n\t\t\t\t20171012162401_DDI127C7","doi-asserted-by":"crossref","unstructured":"Richelda, R., Ronchetti, D., Baldini, L., Cro, L., Viggiano, L., Marzella, R., Rocchi, M., Otsuki, T., Lombardi, L., Maiolo, A.T. et\u00a0al. (1997) A novel chromosomal translocation t(4;14)(p16.3;q32). Blood, 90, 4062\u20134070.","DOI":"10.1182\/blood.V90.10.4062"},{"key":"key\n\t\t\t\t20171012162401_DDI127C8","doi-asserted-by":"crossref","unstructured":"Cappellen, D., De Oliveira, C., Ricol, D., de Medina, S., Bourdin, J., Sastre-Garau, X., Chopin, D., Thiery, J.P. and Radvanyi, F. (1999) Frequent activating mutations of fibroblast growth factor receptor 3 in human bladder and cervix carcinomas. Nat. Genet., 23, 18\u201320.","DOI":"10.1038\/12615"},{"key":"key\n\t\t\t\t20171012162401_DDI127C9","doi-asserted-by":"crossref","unstructured":"Chesi, M., Brents, L.A., Ely, S.A., Bais, C., Robbiani, D.F., Mesri, E.A., Kuehl, W.M. and Bergsagel, P.L. (2001) Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood, 97, 729\u2013736.","DOI":"10.1182\/blood.V97.3.729"},{"key":"key\n\t\t\t\t20171012162401_DDI127C10","doi-asserted-by":"crossref","unstructured":"Ronchetti, D., Greco, A., Compasso, S., Colombo, G., Dell'Era, P., Otsuki, T., Lombardi, L. and Neri, A. (2001) Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations. Oncogene, 20, 3553\u20133562.","DOI":"10.1038\/sj.onc.1204465"},{"key":"key\n\t\t\t\t20171012162401_DDI127C11","doi-asserted-by":"crossref","unstructured":"Li, Z., Zhu, Y.X., Plowright, E.E., Bergsagel, P.L., Chesi, M., Patterson, B., Hawley, T.S., Hawley, R.G. and Stewart, A.K. (2001) The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells. Blood, 97, 2413\u20132419.","DOI":"10.1182\/blood.V97.8.2413"},{"key":"key\n\t\t\t\t20171012162401_DDI127C12","doi-asserted-by":"crossref","unstructured":"Torley, D., Bellus, G.A. and Munro, C.S. (2002) Genes, growth factors and acanthosis nigricans. Br. J. Dermatol., 147, 1096\u20131101.","DOI":"10.1046\/j.1365-2133.2002.05150.x"},{"key":"key\n\t\t\t\t20171012162401_DDI127C13","doi-asserted-by":"crossref","unstructured":"Bellus, G.A., Bamshad, M.J., Przylepa, K.A., Dorst, J., Lee, R.R., Hurko, O., Jabs, E.W., Curry, C.J., Wilcox, W.R., Lachman, R.S. et\u00a0al. (1999) Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN): phenotypic analysis of a new skeletal dysplasia caused by a Lys650Met mutation in fibroblast growth factor receptor 3. Am. J. Med. Genet., 85, 53\u201365.","DOI":"10.1002\/(SICI)1096-8628(19990702)85:1<53::AID-AJMG10>3.0.CO;2-F"},{"key":"key\n\t\t\t\t20171012162401_DDI127C14","doi-asserted-by":"crossref","unstructured":"Baker, K.M., Olson, D.S., Harding, C.O. and Pauli, R.M. (1997) Long-term survival in typical thanatophoric dysplasia type 1. Am. J. Med. Genet., 70, 427\u2013436.","DOI":"10.1002\/(SICI)1096-8628(19970627)70:4<427::AID-AJMG18>3.0.CO;2-J"},{"key":"key\n\t\t\t\t20171012162401_DDI127C15","doi-asserted-by":"crossref","unstructured":"Okajima, K., Asai, K., Niwa, T., Ohki, S., Sobajima, H., Tyson, J., Malcolm, S. and Wada, Y. (2002) Clinical and biochemical findings of a patient with thanatophoric dysplasia type I: additional finding of dicarboxylic aciduria. Cleft Palate-Craniofacial J., 39, 246\u2013248.","DOI":"10.1597\/1545-1569(2002)039<0246:CABFOA>2.0.CO;2"},{"key":"key\n\t\t\t\t20171012162401_DDI127C16","doi-asserted-by":"crossref","unstructured":"Ramirez, A., Bravo, A., Jorcano, J.L. and Vidal, M. (1994) Sequences 5\u2032 of the bovine keratin 5 gene direct tissue- and cell-type-specific expression of a LacZ gene in the adult and during development. Differentiation, 58, 53\u201364.","DOI":"10.1046\/j.1432-0436.1994.5810053.x"},{"key":"key\n\t\t\t\t20171012162401_DDI127C17","doi-asserted-by":"crossref","unstructured":"Fuchs, E. and Raghavan, S. (2002) Getting under the skin of epidermal morphogenesis. Nat. Rev. Genet., 3, 199\u2013209.","DOI":"10.1038\/nrg758"},{"key":"key\n\t\t\t\t20171012162401_DDI127C18","doi-asserted-by":"crossref","unstructured":"Billerey, C., Chopin, D., Aubriot-Lorton, M.H., Ricol, D., Gil Diez de Medina, S., Van Rhijn, B., Bralet, M.P., Lefrere-Belda, M.A., Lahaye, J.B., Abbou, C.C. et\u00a0al. (2001) Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am. J. Pathol., 158, 1955\u20131959.","DOI":"10.1016\/S0002-9440(10)64665-2"},{"key":"key\n\t\t\t\t20171012162401_DDI127C19","doi-asserted-by":"crossref","unstructured":"van Rhijn, B.W., van Tilborg, A.A., Lurkin, I., Bonaventure, J., de Vries, A., Thiery, J.P., van der Kwast, T.H., Zwarthoff, E.C. and Radvanyi, F. (2002) Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders. Eur. J. Hum. Genet., 10, 819\u2013824.","DOI":"10.1038\/sj.ejhg.5200883"},{"key":"key\n\t\t\t\t20171012162401_DDI127C20","doi-asserted-by":"crossref","unstructured":"Tavormina, P.L., Shiang, R., Thompson, L.M., Zhu, Y.Z., Wilkin, D.J., Lachman, R.S., Wilcox, W.R., Rimoin, D.L., Cohn, D.H. and Wasmuth, J.J. (1995) Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. Nat. Genet., 9, 321\u2013328.","DOI":"10.1038\/ng0395-321"},{"key":"key\n\t\t\t\t20171012162401_DDI127C21","doi-asserted-by":"crossref","unstructured":"Tavormina, P.L., Bellus, G.A., Webster, M.K., Bamshad, M.J., Fraley, A.E., McIntosh, I., Szabo, J., Jiang, W., Jabs, E.W. and Wilcox, W.R. et\u00a0al. (1999) A novel skeletal dysplasia with developmental delay and acanthosis nigricans is caused by a Lys650Met mutation in the fibroblast growth factor receptor 3 gene. Am. J. Hum. Genet., 64, 722\u2013731.","DOI":"10.1086\/302275"},{"key":"key\n\t\t\t\t20171012162401_DDI127C22","doi-asserted-by":"crossref","unstructured":"Nakamura, H., Hirota, S., Adachi, S., Ozaki, K., Asada, H. and Kitamura, Y. (2001) Clonal nature of seborrheic keratosis demonstrated by using the polymorphism of the human androgen receptor locus as a marker. J. Invest. Dermatol., 116, 506\u2013510.","DOI":"10.1046\/j.1523-1747.2001.01289.x"},{"key":"key\n\t\t\t\t20171012162401_DDI127C23","doi-asserted-by":"crossref","unstructured":"Li, C., Chen, L., Iwata, T., Kitagawa, M., Fu, X.Y. and Deng, C.X. (1999) A Lys644Glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and ink4 cell cycle inhibitors. Hum. Mol. Genet., 8, 35\u201344.","DOI":"10.1093\/hmg\/8.1.35"},{"key":"key\n\t\t\t\t20171012162401_DDI127C24","doi-asserted-by":"crossref","unstructured":"Iwata, T., Chen, L., Li, C., Ovchinnikov, D.A., Behringer, R.R., Francomano, C.A. and Deng, C.X. (2000) A neonatal lethal mutation in FGFR3 uncouples proliferation and differentiation of growth plate chondrocytes in embryos. Hum. Mol. Genet., 9, 1603\u20131613.","DOI":"10.1093\/hmg\/9.11.1603"},{"key":"key\n\t\t\t\t20171012162401_DDI127C25","doi-asserted-by":"crossref","unstructured":"Chen, L., Li, C., Qiao, W., Xu, X. and Deng, C. (2001) A Ser(365)\u2192Cys mutation of fibroblast growth factor receptor 3 in mouse downregulates Ihh\/PTHrP signals and causes severe achondroplasia. Hum. Mol. Genet., 10, 457\u2013465.","DOI":"10.1093\/hmg\/10.5.457"},{"key":"key\n\t\t\t\t20171012162401_DDI127C26","doi-asserted-by":"crossref","unstructured":"Iwata, T., Li, C.L., Deng, C.X. and Francomano, C.A. (2001) Highly activated Fgfr3 with the K644M mutation causes prolonged survival in severe dwarf mice. Hum. Mol. Genet., 10, 1255\u20131264.","DOI":"10.1093\/hmg\/10.12.1255"},{"key":"key\n\t\t\t\t20171012162401_DDI127C27","doi-asserted-by":"crossref","unstructured":"Takenaka, H., Yasuno, H. and Kishimoto, S. (2002) Immunolocalization of fibroblast growth factor receptors in normal and wounded human skin. Arch. Dermatol. Res., 294, 331\u2013338.","DOI":"10.1007\/s00403-002-0333-z"},{"key":"key\n\t\t\t\t20171012162401_DDI127C28","doi-asserted-by":"crossref","unstructured":"Karoui, M., Hofmann-Radvanyi, H., Zimmermann, U., Couvelard, A., Degott, C., Faridoni-Laurens, L., Ahomadegbe, J.C., Gazzeri, S., Brambilla, E., Clerici, T. et\u00a0al. (2001) No evidence of somatic FGFR3 mutation in various types of carcinoma. Oncogene, 20, 5059\u20135061.","DOI":"10.1038\/sj.onc.1204651"},{"key":"key\n\t\t\t\t20171012162401_DDI127C29","doi-asserted-by":"crossref","unstructured":"Kimura, T., Suzuki, H., Ohashi, T., Asano, K., Kiyota, H. and Eto, Y. (2001) The incidence of thanatophoric dysplasia mutations in FGFR3 gene is higher in low-grade or superficial bladder carcinomas. Cancer, 92, 2555\u20132561.","DOI":"10.1002\/1097-0142(20011115)92:10<2555::AID-CNCR1607>3.0.CO;2-M"},{"key":"key\n\t\t\t\t20171012162401_DDI127C30","doi-asserted-by":"crossref","unstructured":"Cheng, L., Darson, M., Cheville, J.C., Neumann, R.M., Zincke, H., Nehra, A. and Bostwick, D.G. (1999) Urothelial papilloma of the bladder. Clinical and biologic implications. Cancer, 86, 2098\u20132101.","DOI":"10.1002\/(SICI)1097-0142(19991115)86:10<2098::AID-CNCR30>3.0.CO;2-9"},{"key":"key\n\t\t\t\t20171012162401_DDI127C31","doi-asserted-by":"crossref","unstructured":"van Rhijn, B.W., Montironi, R., Zwarthoff, E.C., Jobsis, A.C. and van der Kwast, T.H. (2002) Frequent FGFR3 mutations in urothelial papilloma. J. Pathol., 198, 245\u2013251.","DOI":"10.1002\/path.1202"},{"key":"key\n\t\t\t\t20171012162401_DDI127C32","doi-asserted-by":"crossref","unstructured":"Mauro, M.J., O'Dwyer, M., Heinrich, M.C. and Druker, B.J. (2002) STI571: a paradigm of new agents for cancer therapeutics. J. Clin. Oncol., 20, 325\u2013334.","DOI":"10.1200\/JCO.2002.20.1.325"},{"key":"key\n\t\t\t\t20171012162401_DDI127C33","doi-asserted-by":"crossref","unstructured":"Werner, S., Weinberg, W., Liao, X., Peters, K.G., Blessing, M., Yuspa, S.H., Weiner, R.L. and Williams, L.T. (1993) Targeted expression of a dominant-negative FGF receptor mutant in the epidermis of transgenic mice reveals a role of FGF in keratinocyte organization and differentiation. EMBO J., 12, 2635\u20132643.","DOI":"10.1002\/j.1460-2075.1993.tb05924.x"}],"container-title":["Human Molecular Genetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/hmg\/article-pdf\/14\/9\/1153\/17242292\/ddi127.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T10:51:07Z","timestamp":1586170267000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/hmg\/article\/14\/9\/1153\/619836\/Activating-mutations-of-the-tyrosine-kinase"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3,16]]},"references-count":33,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2005,3,16]]},"published-print":{"date-parts":[[2005,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/hmg\/ddi127","relation":{},"ISSN":["1460-2083","0964-6906"],"issn-type":[{"value":"1460-2083","type":"electronic"},{"value":"0964-6906","type":"print"}],"subject":[],"published-other":{"date-parts":[[2005,5,1]]},"published":{"date-parts":[[2005,3,16]]}}}